SCHEMBL5098384

SCHEMBL5098384

Fc1ccc(-c2[nH]c(S)nc2-c2ccncc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.69
MAPK13 O15264 13/20 0.69
MAPK12 P53778 13/20 0.69
MAPK11 Q15759 13/20 0.69
GCGR P47871 11/20 0.69
CSNK1D P48730 5/20 0.69
MAPK9 P45984 4/20 0.69
PRKD3 O94806 3/20 0.69
MAP4K4 O95819 3/20 0.69
FRK P42685 3/20 0.69
CSNK1A1 P48729 3/20 0.69
GSK3B P49841 3/20 0.69
CLK4 Q9HAZ1 3/20 0.69
PTK6 Q13882 2/20 0.69
PRKD2 Q9BZL6 2/20 0.69
ALOX5 P09917 5/20 0.62
BRAF P15056 2/20 0.62
CSNK1E P49674 3/20 0.61
RAF1 P04049 2/20 0.61
PRKACA P17612 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285506 1.00 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL5435606 0.92 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL9435546 0.90 MAPK13 (0.56) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL15075603 0.82 MAPK11 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL19868925 0.82 MAPK11 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL11267958 0.82 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL27335373 0.81 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL6168758 0.81 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL9340175 0.80 MAPK14 (0.65) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL9339561 0.80 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0011111-B1 5-(4-PYRIDYL)-6-(4-FLUOROPHENYL)-2,3-DIHYDROIMIDAZO-(2,1-B)-THIAZOLE, PROCESS FOR ITS PREPARATION AND MEDICAL COMPOSITION SMITHKLINE BECKMAN CORPORATION (US) 1982-09-22 EP claimed
EP-0011111-A1 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo-(2,1-b)-thiazole, process for its preparation and medical composition SMITHKLINE BECKMAN CORPORATION (US) 1980-05-28 EP claimed
US-7442713-B2 2-thio-substituted imidazole derivatives and their use in pharmaceutics MERCKLE GMBH (DE) 2008-10-28 US disclosed
US-20060252810-A1 2-Thio-substituted imidazole derivatives and their use in pharmaceutics LAUFER STEFAN 2006-11-09 US disclosed
EP-1506187-A1 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS MERCKLE GMBH (DE) 2005-02-16 EP disclosed
WO-2003097633-A1 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS MERCKLE GMBH (DE) 2003-11-27 WO disclosed
EP-0011111-B1 5-(4-PYRIDYL)-6-(4-FLUOROPHENYL)-2,3-DIHYDROIMIDAZO-(2,1-B)-THIAZOLE, PROCESS FOR ITS PREPARATION AND MEDICAL COMPOSITION SMITHKLINE BECKMAN CORPORATION (US) 1982-09-22 EP disclosed
EP-0011111-A1 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo-(2,1-b)-thiazole, process for its preparation and medical composition SMITHKLINE BECKMAN CORPORATION (US) 1980-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252810-A1 2-Thio-substituted imidazole derivatives and their use in pharmaceutics IL2, TPMT, IFNG MAPK14 3913/4885MAPK13 3863/4885MAPK12 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.